XML 162 R22.htm IDEA: XBRL DOCUMENT
v3.26.1

Financial Instruments | 3 Months Ended
--- | ---
Mar. 31, 2026
Investments, All Other Investments [Abstract] |
Financial Instruments | FINANCIAL INSTRUMENTS Fair Value Accounting guidance on fair value measurements specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy: •Level 1 — Quoted prices for identical instruments in active markets. •Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. •Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company also considers counterparty credit risk in its assessment of fair value. The Company determines the fair value of structured liabilities (where performance is linked to structured interest rates, inflation or currency risks) using the Secured Overnight Financing Rate (“Term SOFR”) swap curve and forward interest and exchange rates at period end. Such instruments are classified as Level 2 based on the observability of significant inputs to the model. Instruments classified as Level 3 include the earnout receivable as discussed in Note 12, as well as instruments held in pension asset trusts as discussed in Note 8 of the Company’s 2025 Form 10-K. These valuations take into consideration the Company’s credit risk and its counterparties’ credit risk. The carrying values and the estimated fair values of financial instruments at March 31, 2026 and December 31, 2025 consisted of the following:
| March 31, 2026 |  | December 31, 2025
(DOLLARS IN MILLIONS) | Carrying Value |  | Fair Value |  | Carrying Value |  | Fair Value
LEVEL 1 |  |  |  |  |  |  |
Cash and cash equivalents(1) | $ | 562 |  |  | $ | 562 |  |  | $ | 590 |  |  | $ | 590 |
LEVEL 2 |  |  |  |  |  |  |
Credit facilities and bank overdrafts(2) | 3 |  |  | 3 |  |  | 4 |  |  | 4 |
Derivatives |  |  |  |  |  |  |
Derivative assets(3) | 25 |  |  | 25 |  |  | 18 |  |  | 18 |
Derivative liabilities(3) | 220 |  |  | 220 |  |  | 242 |  |  | 242 |
Commercial paper(2) | 154 |  |  | 154 |  |  | 314 |  |  | 314 |
Long-term debt: |  |  |  |  |  |  |
2026 Euro Notes(4) | 925 |  |  | 920 |  |  | 940 |  |  | 935 |
2027 Notes(4) | 803 |  |  | 768 |  |  | 804 |  |  | 768 |
2028 Notes(4) | 399 |  |  | 399 |  |  | 399 |  |  | 403 |
2030 Notes(4) | 1,238 |  |  | 1,098 |  |  | 1,238 |  |  | 1,113 |
2040 Notes(4) | 341 |  |  | 248 |  |  | 341 |  |  | 255 |
2047 Notes(4) | 392 |  |  | 313 |  |  | 392 |  |  | 322 |
2048 Notes(4) | 674 |  |  | 593 |  |  | 674 |  |  | 607 |
2050 Notes(4) | 888 |  |  | 570 |  |  | 888 |  |  | 585 |
_______________________ (1)The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments. (2)The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments. (3)The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets. (4)The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency. Derivatives Foreign Currency Forward Contracts The Company periodically enters into foreign currency forward contracts with the objective of managing its exchange rate risk related to foreign currency denominated monetary assets and liabilities of its operations. These contracts generally involve the exchange of one currency for a second currency at a future date, have maturities not exceeding twelve months and are with counterparties which are major international financial institutions. Commodity Contracts The Company utilized options that were not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans. These options were transferred as part of the sale of the Soy Crush, Concentrates, and Lecithin business as discussed in Note 3. The Company utilizes swaps that are designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of natural gas used in its manufacturing process. Hedges Related to Issuances of Debt As of March 31, 2026, the Company designated approximately $925 million of Euro Notes as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to foreign exchange movements is recorded in Other comprehensive income (“OCI”) as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). Cross Currency Swaps The Company has twenty-two EUR/USD cross currency swaps with a notional value of approximately $2.4 billion that mature through February 2036. The swaps all qualified as net investment hedges in order to mitigate a portion of the Company’s net European investments from foreign currency risk. As of March 31, 2026, the swaps were in a net liability position with an aggregate fair value of approximately $186 million, which were classified as Other liabilities on the Consolidated Balance Sheets. Changes in fair value related to cross currency swaps are recorded in OCI. The following table shows the notional amount of the Company’s derivative instruments outstanding as of March 31, 2026 and December 31, 2025:
(DOLLARS IN MILLIONS) | March 31, 2026 |  | December 31, 2025
Foreign currency contracts(1) | $ | (1,984) |  |  | $ | (1,840) |
Commodity contracts(1) | 5 |  |  | 11 |
Cross currency swaps | 2,400 |  |  | 1,900 |
_______________________ (1)Foreign currency contracts and commodity contracts are presented net of the outstanding buy/(sell) instruments. The following tables show the Company’s derivative instruments measured at fair value (Level 2 of the fair value hierarchy), as reflected on the Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025:
| March 31, 2026
(DOLLARS IN MILLIONS) | Fair Value of Derivatives Designated as Hedging Instruments |  | Fair Value of Derivatives Not Designated as Hedging Instruments |  | Total Fair Value
Derivative assets(1) |  |  |  |  |
Foreign currency forward contracts | $ | — |  |  | $ | 4 |  |  | $ | 4 |
Cross currency swaps | 18 |  |  | — |  |  | 18 |
Commodity contracts | 3 |  |  | — |  |  | 3 |
Total derivative assets | $ | 21 |  |  | $ | 4 |  |  | $ | 25 |
Derivative liabilities(2) |  |  |  |  |
Foreign currency forward contracts | $ | — |  |  | $ | 16 |  |  | $ | 16 |
Cross currency swaps | 204 |  |  | — |  |  | 204 |
Total derivative liabilities | $ | 204 |  |  | $ | 16 |  |  | $ | 220 |
| December 31, 2025
(DOLLARS IN MILLIONS) | Fair Value of Derivatives Designated as Hedging Instruments |  | Fair Value of Derivatives Not Designated as Hedging Instruments |  | Total Fair Value
Derivative assets(1) |  |  |  |  |
Foreign currency forward contracts | $ | — |  |  | $ | 17 |  |  | $ | 17 |
Cross currency swaps | 1 |  |  | — |  |  | 1 |
Total derivative assets | $ | 1 |  |  | $ | 17 |  |  | $ | 18 |
Derivative liabilities(2) |  |  |  |  |
Foreign currency forward contracts | $ | — |  |  | $ | 3 |  |  | $ | 3 |
Cross currency swaps | 238 |  |  | — |  |  | 238 |
Commodity contracts | 1 |  |  | — |  |  | 1 |
Total derivative liabilities | $ | 239 |  |  | $ | 3 |  |  | $ | 242 |
_______________________ (1)Derivative assets are recorded to Prepaid expenses and other current assets on the Consolidated Balance Sheets. (2)Derivative liabilities are recorded to Other current liabilities and Other liabilities on the Consolidated Balance Sheets. The following table shows the effect of the Company’s derivative instruments which were not designated as hedging instruments on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the three months ended March 31, 2026 and 2025:
| Amount of Gain (Loss) Recognized in Income on Derivative Settlements |  | Amount of Gain (Loss) Recognized in Income on Changes in Fair Value | Location of Gain (Loss) Recognized in Income on Derivative
(DOLLARS IN MILLIONS) | Three Months Ended March 31, |  | Three Months Ended March 31,
2026 |  | 2025 |  | 2026 |  | 2025
Foreign currency forward contracts(1) | $ | (10) |  |  | $ | 22 |  |  | $ | (27) |  |  | $ | 30 |  | Other expense, net
_______________________ (1)The foreign currency contract net gains (losses) offset any recognized gains (losses) arising from the revaluation of the related intercompany loans during the same respective periods. The following table shows the effect of the Company’s derivative and non-derivative instruments designated as cash flow and net investment hedging instruments, net of tax, on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the three months ended March 31, 2026 and 2025:
| Amount of Gain (Loss) Recognized in OCI on Derivative and Non-Derivative (Effective Portion) |  | Location of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income (“AOCI”) into Income (Effective Portion) |  | Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)
| Three Months Ended March 31, |  |  | Three Months Ended March 31,
(DOLLARS IN MILLIONS) | 2026 |  | 2025 |  |  | 2026 |  | 2025
Derivatives in Cash Flow Hedging Relationships: |  |  |  |  |  |  |  |  |
Commodity contracts | $ | 4 |  |  | $ | (1) |  |  | Cost of sales |  | $ | — |  |  | $ | — |
Derivatives in Net Investment Hedging Relationships: |  |  |  |  |  |  |  |  |
Cross currency swaps | 51 |  |  | (31) |  |  | N/A |  | — |  |  | — |
Non-Derivatives in Net Investment Hedging Relationships: |  |  |  |  |  |  |  |  |
2026 Euro Notes | 15 |  |  | (37) |  |  | N/A |  | — |  |  | — |
Tax (expense) benefit | (15) |  |  | 16 |  |  |  |  | — |  |  | — |
Total | $ | 55 |  |  | $ | (53) |  |  |  |  | $ | — |  |  | $ | — |
The ineffective portion of the above noted net investment hedges was approximately $5 million and $4 million for each of the three months ended March 31, 2026 and 2025, respectively, and was recorded as a reduction to Interest expense on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). At March 31, 2026, based on current market rates, the Company does not expect any material derivative losses (net of tax), included in AOCI, to be reclassified into earnings within the next 12 months.

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration